Analysts Are Bullish on These Healthcare Stocks: CASI Pharmaceuticals (CASI), Biogen (BIIB)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on CASI Pharmaceuticals (CASIResearch Report) and Biogen (BIIBResearch Report) with bullish sentiments.

CASI Pharmaceuticals (CASI)

In a report released today, Leland Gershell from Oppenheimer assigned a Buy rating to CASI Pharmaceuticals, with a price target of $5.00. The company’s shares closed last Friday at $2.21.

According to TipRanks.com, Gershell is a 3-star analyst with an average return of 1.8% and a 40.9% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals, BioMarin Pharmaceutical, and Corbus Pharmaceuticals.

Currently, the analyst consensus on CASI Pharmaceuticals is a Moderate Buy with an average price target of $4.25, which is an 114.6% upside from current levels. In a report issued on November 10, H.C. Wainwright also reiterated a Buy rating on the stock with a $3.50 price target.

See today’s analyst top recommended stocks >>

Biogen (BIIB)

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Biogen, with a price target of $300.00. The company’s shares closed last Friday at $244.15, close to its 52-week low of $223.25.

According to TipRanks.com, Olson is a 1-star analyst with an average return of -1.0% and a 39.6% success rate. Olson covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Madrigal Pharmaceuticals, and Frequency Therapeutics.

Currently, the analyst consensus on Biogen is a Hold with an average price target of $293.43, a 20.3% upside from current levels. In a report issued on November 7, Canaccord Genuity also maintained a Buy rating on the stock with a $393.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.